Ozempic and GLP-1 Lawsuits: What New York Patients Need to Know

Few drugs have reshaped American medicine, and American culture, as quickly as Ozempic and the other GLP-1 medications. Originally prescribed for type 2 diabetes and now, increasingly, for weight loss, these drugs are used by millions of people. But alongside their popularity, a major wave of litigation has been building. As of October 2026, more than 4,000 lawsuits are consolidated in federal court alleging that GLP-1 drugs caused severe gastrointestinal injuries, and a second, fast-growing group of lawsuits alleges something even more alarming: permanent vision loss.

Patients considering their legal options deserve a clear picture of this litigation, including, what it is, where it stands, and what it is not. This guide explains the two distinct waves of GLP-1 lawsuits, the injuries behind them, the warning label history at the center of the claims, and what New Yorkers in particular should know about deadlines, evidence, and how their cases would proceed.

What Are GLP-1 Drugs?

GLP-1 receptor agonists mimic a natural hormone that regulates blood sugar and slows the movement of food through the stomach. That slowing effect is part of why the drugs promote weight loss, and it is also at the center of the gastrointestinal injury claims against them.

The medications named in the litigation include Novo Nordisk's semaglutide products, Ozempic, Wegovy, and Rybelsus, along with its liraglutide products, Saxenda and Victoza, and Eli Lilly's drugs, including Mounjaro and Zepbound (tirzepatide) and Trulicity (dulaglutide). Ozempic, approved by the FDA in 2017, is the most prescribed and the most heavily litigated, which is why the entire litigation is often shorthand-labeled the "Ozempic lawsuits," but claims span the entire drug class.

Why Patients Are Filing GLP-1 Lawsuits

These are failure-to-warn cases at their core. Plaintiffs allege that the manufacturers knew or should have known that their drugs could cause severe, sometimes permanent injuries, and that they failed to warn patients and doctors about those risks, warning instead only of milder, transient side effects like nausea. The lawsuits allege that patients who would have made different decisions, or whose doctors would have monitored them differently, were deprived of that choice.

Two distinct injury groups now anchor the litigation, and they are proceeding on separate tracks.

The Gastrointestinal Injury Lawsuits: Gastroparesis, Ileus, and Obstruction

The first and largest wave of lawsuits involves severe gastrointestinal injuries, including:

• Gastroparesis, sometimes called stomach paralysis, in which food moves too slowly through the stomach or stops moving, causing chronic nausea, vomiting, pain, and malnutrition. There is no cure.
• Ileus, in which the intestines stop functioning properly. The FDA added an ileus warning to Ozempic's label in September 2023.
• Intestinal obstruction and pseudo-obstruction, blockages that can require hospitalization and surgery.

Some plaintiffs describe months of persistent vomiting, repeated emergency room visits, hospitalizations, and lasting damage, including, in one of the earliest and most publicized cases, vomiting so severe the plaintiff lost teeth. The first of these lawsuits was filed in August 2023, and in February 2024 the federal cases were consolidated into multidistrict litigation, MDL 3094, in the Eastern District of Pennsylvania. As of October 2026, that MDL holds more than 4,000 cases, with roughly a hundred new filings a month, and the court is working through summary judgment briefing, a significant stage in which rulings on the core claims will shape the litigation's trajectory.

The Vision Loss Lawsuits: NAION

The newer wave of lawsuits involves non-arteritic anterior ischemic optic neuropathy, or NAION, a condition in which blood flow to the optic nerve is cut off, causing sudden, painless, and typically permanent vision loss, often discovered in one eye upon waking. There is no cure, and no FDA-approved treatment.

The scientific attention began in earnest with a 2024 study in JAMA Ophthalmology reporting that diabetic patients taking semaglutide faced a more than fourfold increased risk of NAION, and overweight patients taking it for weight loss a more than sevenfold increased risk. A large Dutch study the same year found more than double the risk among diabetic semaglutide users, and research presented to the American Academy of Ophthalmology in late 2025 reinforced the association. In June 2025, the World Health Organization advised that semaglutide drugs may rarely cause NAION, and European regulators concluded it is a very rare side effect, affecting roughly 1 in 10,000 users. The FDA, notably, has not required a NAION warning on U.S. labels, and that gap is precisely what the lawsuits target.

The federal vision loss cases were consolidated into their own MDL, MDL 3163, in December 2025, before the same judge who oversees the gastroparesis litigation. These cases are earlier in their life cycle: leadership was appointed in March 2026, the court held a Science Day in June 2026 to hear the competing expert positions, and filings passed 200 federal cases by this fall, with steady monthly growth. For patients who suffered unexplained sudden vision loss while on a GLP-1 drug, this is the track their claims would follow.

The Ozempic Warning Label Timeline

Because these are failure-to-warn cases, the history of what the labels said, and when, matters enormously:

• 2017: The FDA approves Ozempic. The label warns of common gastrointestinal side effects but not gastroparesis.
• September 2023: After case reports accumulate, the FDA adds ileus to the Ozempic label, weeks after the first gastroparesis lawsuit is filed.
• January 2025: The label is updated to state the drug is not recommended for patients with severe gastroparesis, while still not warning that the drug may cause the condition.
• October 2025: Intestinal obstruction and severe constipation are added to the label's postmarketing adverse reactions at the FDA's request.
• Through 2026: No U.S. label warns of NAION, despite the WHO advisory, the European findings, and the published studies. In March 2026, the FDA sent Novo Nordisk a warning letter over deficiencies in its side effect reporting.

Plaintiffs' core argument writes itself from this chronology: warnings arrived late, arrived incompletely, or have not arrived at all, and patients were injured in the meantime.

Where the GLP-1 Litigation Stands as of October 2026

The structure of the litigation is worth understanding, because it determines how any individual case proceeds. These are not class actions. Each plaintiff files an individual lawsuit, and the federal cases are coordinated in the two MDLs in the Eastern District of Pennsylvania for pretrial purposes: MDL 3094 for gastrointestinal injuries and MDL 3163 for NAION, both before Judge Karen Marston. A parallel set of cases is coordinated in New Jersey state court, where Novo Nordisk's U.S. headquarters is located, with the New Jersey Supreme Court having approved consolidated multicounty litigation for both injury types in late 2025.

Honesty about the posture matters, because advertising around this litigation often implies otherwise: as of October 2026, there have been no trials and no settlements, global or otherwise, in either MDL. The gastroparesis cases are at the summary judgment stage, the vision loss cases are in coordinated discovery, and bellwether test trials, the usual precursor to any mass settlement, lie ahead. Patients should be wary of anyone promising specific payouts in litigation where no case has yet been tried or resolved. What can be said is that consolidated litigation of this scale exists precisely to resolve thousands of claims efficiently, and that the plaintiffs who are positioned best when resolutions come are those whose cases were investigated, documented, and filed properly.

What This Means for New York Patients

GLP-1 litigation is national, but a New Yorker's case starts here, and several New York-specific points matter.

How a New York case proceeds. A lawsuit filed by a New York patient in federal court is transferred to the appropriate MDL in Pennsylvania for coordinated pretrial proceedings, or may be filed among the coordinated cases in New Jersey state court. Either way, the client works with their own attorneys, and if the case is not resolved in the coordinated proceedings, it can return for trial. The MDL structure changes where the pretrial work happens; it does not change who stands up for the individual client.

The deadline question. New York generally allows three years from injury to file a product liability claim, and in failure-to-warn pharmaceutical cases, questions about when that clock starts, including how New York's discovery rules apply to a toxic exposure injury that develops over time, can be complex and unforgiving. A patient who developed gastroparesis in 2023 and a patient diagnosed with NAION last month are in very different limitations postures. The only safe approach is to have the deadline analyzed by an attorney now, not after it has been missed, because no coordinated proceeding revives a claim that expired before filing.

The evidence lives in your New York medical records. For gastrointestinal claims, the litigation has effectively standardized around objective proof: a gastric emptying study confirming gastroparesis, together with records showing prolonged symptoms, typically persistent vomiting lasting a month or more, and the prescription history tying the injury to the drug. For NAION claims, the foundation is the ophthalmological workup diagnosing NAION and ruling out mimicking conditions. New York patients have access to some of the best gastroenterology and neuro-ophthalmology practices in the country, and building the case means gathering those records, pharmacy histories, and treatment timelines promptly and completely.

One medical caution. No one should stop taking a prescribed medication because of litigation headlines. Decisions about continuing or discontinuing a GLP-1 drug belong with the patient and their doctor. What belongs with a lawyer is the separate question of whether an injury that has already happened supports a claim.

Warning Signs Patients Should Not Ignore

Both injury types at the center of this litigation announce themselves through symptoms that patients, and sometimes their doctors, initially attribute to the drugs' expected side effects. Recognizing the difference matters medically first and legally second.

For gastrointestinal injury, the line between ordinary GLP-1 side effects and something serious is duration and severity. Transient nausea early in treatment is common. What is not ordinary: vomiting that persists for weeks, vomiting undigested food eaten many hours earlier, feeling full after a few bites or long after meals, severe bloating and abdominal pain, the inability to pass gas, and unintended malnutrition. Those are the symptoms that lead to gastric emptying studies, emergency room visits, and, in the lawsuits, gastroparesis and obstruction diagnoses.

For vision, the warning signs are more sudden and absolute: painless vision loss in one eye, often noticed on waking, a shadow or darkened area in the visual field, blind spots, newly blurry or dim vision, or washed-out color perception. NAION is diagnosed through clinical ophthalmological examination, and because some conditions that mimic it are medical emergencies in their own right, sudden vision changes warrant immediate care, not a wait-and-see approach.

In both cases, the medical record created at the moment symptoms are reported becomes the backbone of any later legal claim. Patients who report symptoms promptly, get the objective testing, and follow through with treatment protect their health and, incidentally, their legal rights at the same time.

Who May Qualify for a GLP-1 Lawsuit in New York

Qualification criteria in mass litigation evolve as the science and court rulings develop, but as of now, the cases being accepted generally involve:

• For gastrointestinal claims: use of a GLP-1 drug followed by a diagnosed severe gastrointestinal injury, with gastroparesis typically confirmed by a gastric emptying study and accompanied by severe, prolonged symptoms such as weeks of persistent vomiting, hospitalization, or emergency treatment
• For vision claims: use of a GLP-1 drug followed by a diagnosis of NAION or comparable documented vision loss

Certain histories can complicate or disqualify a claim, such as prior gastric bypass or similar bariatric surgery before taking the drug in gastrointestinal cases. These screens are guidelines rather than verdicts, and the honest answer is that only a case-specific review of the medical records can say whether a claim is viable. That review costs nothing, and having it done early preserves every option.

Compensation in GLP-1 Lawsuits

Plaintiffs whose claims succeed may recover compensation for medical expenses, past and future, including the ongoing care that incurable conditions like gastroparesis and NAION demand; lost income and diminished earning capacity, which can be substantial where vision loss ends a career or chronic illness makes full-time work impossible; and pain and suffering, including the daily reality of living with a permanent injury that adequate warnings might have prevented.

Because no GLP-1 case has yet settled or gone to verdict, any specific dollar figure attached to these cases today is speculation, and this firm does not traffic in speculation. What determines the value of an individual claim, here as in all product liability cases, is the severity and permanence of the injury, the strength of the medical proof, the economic losses, and the quality of the case's preparation.

Frequently Asked Questions About Ozempic and GLP-1 Lawsuits

Is the Ozempic lawsuit a class action?

No. These are individual lawsuits coordinated for pretrial purposes in multidistrict litigation: MDL 3094 in the Eastern District of Pennsylvania for gastrointestinal injuries and MDL 3163 for NAION vision loss, with parallel coordinated cases in New Jersey state court. Each patient's case remains their own, with compensation based on their individual injuries.

Has there been an Ozempic settlement yet?

No. As of October 2026, there have been no settlements and no trials in either the gastrointestinal or vision loss litigation. The gastroparesis cases are at the summary judgment stage and the NAION cases are in coordinated discovery. Anyone promising a specific payout at this stage is speculating.

What injuries qualify for a GLP-1 lawsuit?

The gastrointestinal track involves gastroparesis (typically confirmed by a gastric emptying study), ileus, and intestinal obstruction, usually with severe prolonged symptoms such as weeks of persistent vomiting or hospitalization. The vision track involves NAION, a sudden and typically permanent loss of vision caused by interrupted blood flow to the optic nerve. Only a review of your medical records can confirm whether your case qualifies.

Which drugs are included in the GLP-1 litigation?

Claims involve Novo Nordisk's semaglutide drugs (Ozempic, Wegovy, Rybelsus) and liraglutide drugs (Saxenda, Victoza), and Eli Lilly's tirzepatide drugs (Mounjaro, Zepbound) and Trulicity. Ozempic is the most heavily litigated, but patients injured by other drugs in the class may also have claims.

How long do I have to file a GLP-1 lawsuit in New York?

New York generally allows three years for product liability claims, but when that period begins in a pharmaceutical injury case can involve complex questions about when the injury and its cause were or should have been discovered. Because the answer is case-specific and the consequence of a miss is total, patients should have their deadline evaluated by an attorney promptly.

Should I stop taking Ozempic if I am worried about these risks?

Do not stop taking any prescribed medication without talking to your doctor. Decisions about your treatment belong with you and your physician. If you experience severe symptoms such as persistent vomiting, intense abdominal pain, or any sudden change in your vision, seek medical attention immediately, and if you have already suffered a serious injury, a lawyer can separately evaluate whether you have a claim.